These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 18296048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Optimization of 2,3,5-trisubstituted pyridine derivatives as potent allosteric Akt1 and Akt2 inhibitors.
    Hartnett JC, Barnett SF, Bilodeau MT, Defeo-Jones D, Hartman GD, Huber HE, Jones RE, Kral AM, Robinson RG, Wu Z.
    Bioorg Med Chem Lett; 2008 Mar 15; 18(6):2194-7. PubMed ID: 18294842
    [Abstract] [Full Text] [Related]

  • 3. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
    Wu Z, Hartnett JC, Neilson LA, Robinson RG, Fu S, Barnett SF, Defeo-Jones D, Jones RE, Kral AM, Huber HE, Hartman GD, Bilodeau MT.
    Bioorg Med Chem Lett; 2008 Feb 15; 18(4):1274-9. PubMed ID: 18249537
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.
    Zhu GD, Gong J, Gandhi VB, Woods K, Luo Y, Liu X, Guan R, Klinghofer V, Johnson EF, Stoll VS, Mamo M, Li Q, Rosenberg SH, Giranda VL.
    Bioorg Med Chem; 2007 Mar 15; 15(6):2441-52. PubMed ID: 17258463
    [Abstract] [Full Text] [Related]

  • 7. Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
    Bencsik JR, Xiao D, Blake JF, Kallan NC, Mitchell IS, Spencer KL, Xu R, Gloor SL, Martinson M, Risom T, Woessner RD, Dizon F, Wu WI, Vigers GP, Brandhuber BJ, Skelton NJ, Prior WW, Murray LJ.
    Bioorg Med Chem Lett; 2010 Dec 01; 20(23):7037-41. PubMed ID: 20971641
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Discovery of pyrrolopyrimidine inhibitors of Akt.
    Blake JF, Kallan NC, Xiao D, Xu R, Bencsik JR, Skelton NJ, Spencer KL, Mitchell IS, Woessner RD, Gloor SL, Risom T, Gross SD, Martinson M, Morales TH, Vigers GP, Brandhuber BJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5607-12. PubMed ID: 20810279
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Aminofurazans as potent inhibitors of AKT kinase.
    Rouse MB, Seefeld MA, Leber JD, McNulty KC, Sun L, Miller WH, Zhang S, Minthorn EA, Concha NO, Choudhry AE, Schaber MD, Heerding DA.
    Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1508-11. PubMed ID: 19179070
    [Abstract] [Full Text] [Related]

  • 13. Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.
    Zhu GD, Gong J, Claiborne A, Woods KW, Gandhi VB, Thomas S, Luo Y, Liu X, Shi Y, Guan R, Magnone SR, Klinghofer V, Johnson EF, Bouska J, Shoemaker A, Oleksijew A, Stoll VS, De Jong R, Oltersdorf T, Li Q, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3150-5. PubMed ID: 16603355
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q, Bourbeau MP, Wohlhieter GE, Yao G, Monenschein H, Rider JT, Lee MR, Zhang S, Lofgren J, Freeman D, Li C, Tominey E, Huang X, Hoffman D, Yamane H, Tasker AS, Dominguez C, Viswanadhan VN, Hungate R, Zhang X.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1652-6. PubMed ID: 20137932
    [Abstract] [Full Text] [Related]

  • 16. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.
    Li Q, Li T, Zhu GD, Gong J, Claibone A, Dalton C, Luo Y, Johnson EF, Shi Y, Liu X, Klinghofer V, Bauch JL, Marsh KC, Bouska JJ, Arries S, De Jong R, Oltersdorf T, Stoll VS, Jakob CG, Rosenberg SH, Giranda VL.
    Bioorg Med Chem Lett; 2006 Mar 15; 16(6):1679-85. PubMed ID: 16403626
    [Abstract] [Full Text] [Related]

  • 17. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.
    Lindsley CW, Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME.
    Bioorg Med Chem Lett; 2005 Feb 01; 15(3):761-4. PubMed ID: 15664853
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway.
    Kim MJ, Kim HB, Bae JH, Lee JW, Park SJ, Kim DW, Park SI, Kang CD, Kim SH.
    Biochem Pharmacol; 2009 Sep 15; 78(6):573-82. PubMed ID: 19464267
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.